Surface Expression of Collagen Receptor Fc Receptor-γ/Glycoprotein VI Is Enhanced on Platelets in Type 2 Diabetes and Mediates Release of CD40 Ligand and Activation of Endothelial Cells
- Natalia Cabeza1,
- Zhongyan Li1,
- Christian Schulz1,
- Elisabeth Kremmer2,
- Steffen Massberg1,
- Andreas Bültmann1 and
- Meinrad Gawaz1
- 1Medizinische Klinik Klinikum rechts der Isar and Deutsches Herzzentrum, Technische Universität München, München, Germany
- 2Institute of Molecular Immunology, GSF-National Research Center for Environment and Health, München, Germany
- Address correspondence and reprint requests to Meinrad Gawaz, MD, Medizinische Klinik, Klinikum rechts der IsarDeutsches Herzzentrum, Technische Universität München, Ismaningerstraße 22, 81675 München, Germany. E-mail: meinrad.gawaz{at}med1.med.tu-muenchen.de
Abstract
Diabetes is associated with an enhanced collagen-mediated platelet activation that contributes significantly to thromboischemic complications. In this study, the platelet collagen receptor glycoprotein VI (GPVI) was studied in 385 patients with type 2 diabetes. Surface expression of the platelet Fc receptor that forms a functional complex with GPVI was significantly increased in patients with diabetes compared with those without diabetes (P = 0.02). Fc receptor expression correlated with GPVI expression and was found to be independently associated with diabetes (r = 0.529, P < 0.001). Stimulation of GPVI through a specific anti-GPVI monoclonal antibody significantly enhanced surface expression of CD40L (P = 0.006). Because CD40L is a potent platelet-derived cytokine that is involved in thrombosis and atherosclerosis, we evaluated the effect of GPVI-mediated release of CD40L on activation of endothelial cells. Coincubation of GPVI-stimulated platelets resulted in substantial enhanced endothelial surface expression of CD62P, αvβ3, and intercellular adhesion molecule 1 (P < 0.05) and secretion of monocyte chemoattractant protein 1 of cultured human umbilical vein endothelial cells (P < 0.01). These results suggest that the function of collagen receptor GPVI is altered in type 2 diabetes and may play an important role in atherothrombotic complications. Inhibition of GPVI may be a promising pharmacological target in the treatment of high-risk diabetic patients.
- GPVI, glycoprotein VI
- HUVEC, human umbilical vein endothelial cell
- ICAM-1, intercellular adhesion molecule 1
- mAb, monoclonal antibody
- MCP-1, monocyte chemoattractant protein 1
- VCAM-1, vascular cell adhesion molecule-1
Footnotes
-
N.C. and Z.L. contributed equally to this work.
-
- Accepted April 19, 2004.
- Received August 11, 2004.
- DIABETES














